Drug Trial Radar · NCT06294301
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Nov 23, 2023
Primary completion
Aug 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
LP-005 Dose 1 (Single)Biological
A single dose of LP-005 (Dose 1) was administered intravenously.
LP-005 Dose 2 (Single)Biological
A single dose of LP-005 (Dose 2) was administered intravenously.
LP-005 Dose 3 (Single)Biological
A single dose of LP-005 (Dose 3) was administered intravenously.
LP-005 Dose 4 (Single)Biological
A single dose of LP-005 (Dose 4) was administered intravenously.
LP-005 Dose 5 (Single)Biological
A single dose of LP-005 (Dose 5) was administered intravenously.
LP-005 Dose 6 (Single)Biological
A single dose of LP-005 (Dose 6) was administered intravenously.
Placebo (Single)Biological
A single dose of placebo was administered intravenously.
LP-005 Dose 7 (Multiple)Biological
LP-005 (Dose 7) was administered multiple times intravenously.
LP-005 Dose 8 (Multiple)Biological
LP-005 (Dose 8) was administered multiple times intravenously.
LP-005 Dose 9 (Multiple)Biological
LP-005 (Dose 9) was administered multiple times intravenously.
Placebo (Multiple)Biological
Placebo was administered multiple times intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Observation for 78 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.